This biosimilar 6-pack safety study, conducted in 2014 by Product Safety Labs (USA), established a robust safety profile for ION-ZC1 at 100% concentration, even in its non-cGMP prototype form. The comprehensive analysis evaluated six different toxicological endpoints across three animal species, forming a regulatory-ready toxicology package.
The only mild effect observed was slight eye irritation, while all other tests showed no significant adverse reactions, confirming ION-ZC1’s biosafety for potential pharmaceutical development.
Study Design: 6-Pack Safety Evaluation
Topical & Dermal:
Systemic:
Concentration tested: 100% (non-cGMP biosimilar)
Result: No systemic toxicity, only mild eye irritancy reported
Conducted by: Product Safety Labs, USA
This comprehensive biosafety toxicity study reinforces ION-ZC1’s viability in advanced drug delivery platforms, including:
Each safety endpoint met or exceeded FDA and OECD reference criteria for non-toxic classification, especially impressive at a full-strength, pre-formulation concentration.
ION-ZC1 combines redox-active metals like zinc, copper, and magnesium with hydrogen and sulfur ligands. Evaluating its safety across multiple administration routes was essential to validate its potential:
This supports its development into pharmaceutical-grade versions such as Ion Gel ZCM-25®, where concentrations are significantly lower (25%) and further refined under cGMP.
Additionally, the redox and ionophore activity of ION-ZC1 plays a critical role in cellular processes relevant to healing and inflammation. Its metal-based coordination complex creates an ionic environment that can influence oxidative stress responses and modulate immune signals, offering far-reaching implications for dermatological and systemic therapies.
The presence of biologically available ions like Zn²⁺ and Cu²⁺ is particularly important. These ions contribute to enzymatic activity, tissue regeneration, and antimicrobial action. In clinical models, these properties have translated into visible healing progress, as seen in diabetic foot and post-surgical wound recovery studies using the cGMP Ion Gel ZCM-25® formula.
With antimicrobial resistance (AMR) on the rise globally and healthcare-associated infections (HAIs) posing major economic burdens, safe alternatives to traditional antibiotics are urgently needed. ION-ZC1’s demonstrated biocidal potential against pathogens such as MRSA, Acinetobacter baumannii, and SARS-CoV-2 further emphasizes its value in next-generation therapies.
Unlike many small-molecule antimicrobials, ION-ZC1’s effects are mechanical and redox-based, making resistance development highly unlikely. The 100% concentration study proves that even at maximal exposure, the biosimilar does not induce systemic toxicity, making it suitable for scalable pharmaceutical development.
This verified biosafety study confirms that ION-ZC1 is well tolerated at 100% concentration, demonstrating a high safety margin across topical, systemic, and mucosal exposures. These results support its safe use in advanced clinical applications.
Today, Ion Gel ZCM-25®—formulated at only 25% concentration of ION-ZC1—is already approved as a Class II Medical Device in Mexico and is actively used for infection prevention and wound healing. Its development was grounded in studies like this one, where foundational safety was meticulously established and documented.
As we look toward future applications, this data not only justifies regulatory advancement but also paves the way for innovative formulations that address critical unmet medical needs in infectious disease control, chronic wound care, and inflammation-driven disorders.
Learn More. Explore safety studies and human tolerability research: https://zcm25.com/resources